BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26242829)

  • 1. DNMT3A intragenic hypomethylation is associated with adverse prognosis in acute myeloid leukemia.
    Zhang YY; Yao DM; Zhu XW; Zhou JD; Ma JC; Yang J; Wen XM; Guo H; Lin J; Qian J
    Leuk Res; 2015 Oct; 39(10):1041-7. PubMed ID: 26242829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
    Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
    J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome.
    Zhang YY; Zhou JD; Yang DQ; He PF; Yao DM; Qian Z; Yang J; Xu WR; Lin J; Qian J
    Clin Chem Lab Med; 2018 Feb; 56(3):485-491. PubMed ID: 29031013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia.
    Ibrahem L; Mahfouz R; Elhelw L; Abdsalam EM; Soliman R
    Blood Cells Mol Dis; 2015 Jan; 54(1):84-9. PubMed ID: 25172541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant hypomethylation of SALL4 gene is associated with intermediate and poor karyotypes in acute myeloid leukemia.
    Ma JC; Qian J; Lin J; Qian W; Yang J; Wang CZ; Chai HY; Li Y; Chen Q; Qian Z
    Clin Biochem; 2013 Mar; 46(4-5):304-7. PubMed ID: 23201546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemia.
    Zhu XW; Wen XM; Zhang YY; Yang L; Guo H; Yang J; Zhang M; Yin JY; Ma JC; Lin J; Deng ZQ; Qian J
    Int J Clin Exp Pathol; 2015; 8(5):4321-31. PubMed ID: 26191124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of CTNNA1 promoter: frequent but not an adverse prognostic factor in acute myeloid leukemia.
    Chen XX; Lin J; Qian J; Qian W; Yang J; Ma JC; Deng ZQ; An C; Tang CY; Qian Z; Liu Q
    Leuk Res; 2014 May; 38(5):613-8. PubMed ID: 24685333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
    El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
    Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.
    Sehgal AR; Gimotty PA; Zhao J; Hsu JM; Daber R; Morrissette JD; Luger S; Loren AW; Carroll M
    Clin Cancer Res; 2015 Apr; 21(7):1614-20. PubMed ID: 25609058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation.
    Hájková H; Marková J; Haškovec C; Sárová I; Fuchs O; Kostečka A; Cetkovský P; Michalová K; Schwarz J
    Leuk Res; 2012 Sep; 36(9):1128-33. PubMed ID: 22749068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
    Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
    Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients.
    Shivarov V; Gueorguieva R; Stoimenov A; Tiu R
    Leuk Res; 2013 Nov; 37(11):1445-50. PubMed ID: 23962568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of the GATA binding protein 4 (GATA4) promoter in Chinese pediatric acute myeloid leukemia.
    Tao YF; Fang F; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Li ZH; Wang NN; Xu LX; Du XJ; Sun LC; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
    BMC Cancer; 2015 Oct; 15():756. PubMed ID: 26490736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DDX43 promoter is frequently hypomethylated and may predict a favorable outcome in acute myeloid leukemia.
    Lin J; Chen Q; Yang J; Qian J; Deng ZQ; Qian W; Chen XX; Ma JC; Xiong DS; Ma YJ; An C; Tang CY
    Leuk Res; 2014 May; 38(5):601-7. PubMed ID: 24656837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.
    Zhou JD; Zhang TJ; Wang YX; Yang DQ; Yang L; Ma JC; Wen XM; Yang J; Lin J; Qian J
    Tumour Biol; 2016 Jul; 37(7):8951-60. PubMed ID: 26753961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes.
    Qu Y; Lennartsson A; Gaidzik VI; Deneberg S; Karimi M; Bengtzén S; Höglund M; Bullinger L; Döhner K; Lehmann S
    Epigenetics; 2014 Aug; 9(8):1108-19. PubMed ID: 24866170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia.
    Zhang TJ; Qian Z; Wen XM; Zhou JD; Li XX; Xu ZJ; Ma JC; Zhang ZH; Lin J; Qian J
    Pathol Res Pract; 2018 Jun; 214(6):896-901. PubMed ID: 29627222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.